HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Nodality enters into a strategic collaboration with Johnson & Johnson Innovation in autoimmune diseases
A strategic collaboration has been facilitated by the Johnson & Johnson Innovation Center in California under an agreement with Janssen Biotech, Inc. to apply Nodality's proprietary Single Cell Network Profiling (SCNP) technology to immunology R&D programs. The goal of the collaboration is to improve the development and probability of success of compounds for the treatment of rheumatoid arthritis and inflammatory bowel disease by further understanding the biologic function and activity at the single cell level. The agreement also provides an option to develop companion diagnostics that may arise from the collaboration.

Under the terms of the agreement, Nodality will receive an upfront payment and support for research activities.

Laura Brege, President and Chief Executive Officer of Nodality, said, "We are excited to apply our technology to enhance the drug discovery activities of Janssen. This collaboration is our third major strategic pharmaceutical partnership applying SCNP to drug development. We look forward to providing Janssen with clinically and commercially actionable results and to working closely with their teams."

It is widely acknowledged that biologic profiling of individual patients and diseases from a systems biology perspective can improve therapeutic development and use. Much of the difficulty in drug development stems from the complexity of the biology involved and the incomplete understanding of the pathogenesis of different diseases. Nodality's SCNP is designed to better understand this pathogenesis and heterogeneity and therefore patients' responses to therapies. Nodality currently uses SCNP to validate therapeutic targets, compare agents against these targets, efficiently advance targeted agents, and develop novel diagnostics.

"SCNP provides a network level view of protein pathways, cellular networks, and cell-cell interactions. Nodality is therefore able to improve the definition of disease states, drug activities, and patient responses," noted Nodality's Chief Medical Officer Alessandra Cesano, M.D., Ph.D. "With its unique combination of advantages, Nodality aims to create novel, clinically actionable and commercially important information that can improve patient care."

Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy